DISRUPT

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Individuals with known or suspected complicated S. Aureus Blood Stream Infection

Diagnosis Required

Known or suspected complicated S. Aureus Blood Stream Infection

Diseases Being Studied

S. Aureus Blood Stream Infection
Location: San Antonio, TX

Sponsor: ContraFect

Coordinating Center/CRO: Covance

Primary Objective: To determine if exebacasein addition to standard-of-care antibiotics (SoCA) is superior to SoCAalone for clinical responder rate at Day 14 in patients with MRSA bloodstream infections (BSI), including infective endocarditis (IE) (i.e., the MRSA population) in the microbiological intent-to-treat (mITT) analysis set

Study drugs: Exebacasevs. Placebo

Sample size: 348

Start up status: Coverage analysis almost complete; will submit to IRB as soon as coverage analysis complete and budget agreed upon

Meet Your Clinical Research Team

Contact us

Principal Investigator: All Infectious Diseases Faculty

For questions, please contact Dr. Barbara Taylor